MA37951B2 - Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium - Google Patents

Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium

Info

Publication number
MA37951B2
MA37951B2 MA37951A MA37951A MA37951B2 MA 37951 B2 MA37951 B2 MA 37951B2 MA 37951 A MA37951 A MA 37951A MA 37951 A MA37951 A MA 37951A MA 37951 B2 MA37951 B2 MA 37951B2
Authority
MA
Morocco
Prior art keywords
irbesartane
atorvastatin
magnesium carbonate
tablet formulation
bilayer tablet
Prior art date
Application number
MA37951A
Other languages
English (en)
Other versions
MA37951A1 (fr
Inventor
Yong Il Kim
Jung Hyun Cho
Jun Young Choi
Young Keun Choi
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37951(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MA37951A1 publication Critical patent/MA37951A1/fr
Publication of MA37951B2 publication Critical patent/MA37951B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation de comprimé composite bicouche comprenant (a) une première couche comportant de l'irbesartane ou son sel pharmaceutiquement acceptable, et (b) une seconde couche comportant de l'atorvastatine ou son sel pharmaceutiquement acceptable et du carbonate de magnésium (m
MA37951A 2012-08-31 2013-08-30 Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium MA37951B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120096477A KR20140028971A (ko) 2012-08-31 2012-08-31 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
PCT/KR2013/007838 WO2014035188A1 (fr) 2012-08-31 2013-08-30 Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium

Publications (2)

Publication Number Publication Date
MA37951A1 MA37951A1 (fr) 2018-06-29
MA37951B2 true MA37951B2 (fr) 2019-12-31

Family

ID=50183917

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37951A MA37951B2 (fr) 2012-08-31 2013-08-30 Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium

Country Status (31)

Country Link
US (1) US20150209290A1 (fr)
EP (1) EP2890368A4 (fr)
JP (1) JP6363079B2 (fr)
KR (1) KR20140028971A (fr)
CN (1) CN104602677A (fr)
AR (1) AR092386A1 (fr)
AU (1) AU2013309686B2 (fr)
BR (1) BR112015004471A8 (fr)
CA (1) CA2882735A1 (fr)
CL (1) CL2015000402A1 (fr)
CR (1) CR20150115A (fr)
DO (1) DOP2015000040A (fr)
EA (1) EA030306B1 (fr)
EC (1) ECSP15010600A (fr)
GT (1) GT201500043A (fr)
IL (1) IL237424A0 (fr)
IN (1) IN2015DN01463A (fr)
MA (1) MA37951B2 (fr)
MX (1) MX354800B (fr)
MY (1) MY175897A (fr)
NI (1) NI201500027A (fr)
NZ (1) NZ706472A (fr)
PE (1) PE20150935A1 (fr)
PH (1) PH12015500394A1 (fr)
RU (1) RU2015111546A (fr)
SG (1) SG11201500584YA (fr)
TW (1) TWI651101B (fr)
UA (1) UA115995C2 (fr)
UY (1) UY35001A (fr)
WO (1) WO2014035188A1 (fr)
ZA (1) ZA201502156B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6981088B2 (ja) * 2017-01-27 2021-12-15 ニプロ株式会社 経口固形製剤
UA125535C2 (uk) * 2017-07-17 2022-04-13 Елі Ліллі Енд Компані Фармацевтичні композиції

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
PE20030324A1 (es) 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
TW200812619A (en) * 2006-04-06 2008-03-16 Schering Corp TRA combination therapies
KR20090114323A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 약제학적 제제
WO2011121824A1 (fr) * 2010-03-29 2011-10-06 アステラス製薬株式会社 Comprimé à désintégration orale
KR101248804B1 (ko) 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제

Also Published As

Publication number Publication date
AU2013309686A1 (en) 2015-02-26
SG11201500584YA (en) 2015-02-27
CA2882735A1 (fr) 2014-03-06
IL237424A0 (en) 2015-04-30
AR092386A1 (es) 2015-04-22
MY175897A (en) 2020-07-14
BR112015004471A8 (pt) 2019-08-27
GT201500043A (es) 2017-08-24
BR112015004471A2 (pt) 2017-07-04
JP6363079B2 (ja) 2018-07-25
WO2014035188A1 (fr) 2014-03-06
DOP2015000040A (es) 2015-04-15
MA37951A1 (fr) 2018-06-29
CL2015000402A1 (es) 2015-06-05
AU2013309686B2 (en) 2017-09-07
CR20150115A (es) 2015-04-16
JP2015530384A (ja) 2015-10-15
TWI651101B (zh) 2019-02-21
EA030306B1 (ru) 2018-07-31
IN2015DN01463A (fr) 2015-07-03
PE20150935A1 (es) 2015-06-20
MX2015002526A (es) 2015-06-23
EP2890368A4 (fr) 2016-03-02
TW201414507A (zh) 2014-04-16
MX354800B (es) 2018-03-22
PH12015500394A1 (en) 2015-04-27
UA115995C2 (uk) 2018-01-25
CN104602677A (zh) 2015-05-06
ECSP15010600A (es) 2015-12-31
EP2890368A1 (fr) 2015-07-08
NI201500027A (es) 2017-01-04
RU2015111546A (ru) 2016-10-20
KR20140028971A (ko) 2014-03-10
ZA201502156B (en) 2016-07-27
UY35001A (es) 2014-03-31
EA201590469A1 (ru) 2015-06-30
US20150209290A1 (en) 2015-07-30
NZ706472A (en) 2018-02-23

Similar Documents

Publication Publication Date Title
BR112012024139A2 (pt) formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide.
WO2012177443A3 (fr) Co-agonistes du récepteur du glucagon et du récepteur du gpl-1
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
EP2814939A4 (fr) Détecteur de nanopore pour la translocation de protéine à médiation par enzyme
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
NL1031503A1 (nl) Stereoscopisch beeldscherm voor omschakelen tussen 2D/3D beelden.
GB2481713B (en) Switchable 3-dimensional conversion device, method for manufacturing the same and stereoscopic image display device using the same
EP3020717A4 (fr) Antagoniste des récepteurs p2x4
UA107967C2 (en) Pharmaceutical composition in the form of bilayer tablets which contain inhibitor of hmg-coa reductase inhibitor and irbesartan
WO2015073710A3 (fr) Détection du risque de maladie cardiovasculaire athéroscléreuse et du risque d'infarctus du myocarde
SG11201510134YA (en) Real-time multi-functional ecg signal processing system, dspe for the ecg signal processing system, and method thereof
EA201390335A1 (ru) Введение лоркасерина индивидуумам с почечной недостаточностью
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
IT1397313B1 (it) Unita' di taglio per macchina o pressa di termoforatura e macchina di termoforatura dotata di tale unita' di taglio.
MA37951B2 (fr) Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium
MA34709B1 (fr) Compositions pharmaceutiques
WO2011097527A3 (fr) Immunoprotection de fractions thérapeutiques avec des régions fc améliorées
MX364626B (es) Péptidos miméticos.
IN2015DN01018A (fr)
WO2011136489A3 (fr) Capteur d'image pour capsule endoscopique permettant un fonctionnement à deux modes
EP3979902A4 (fr) Capteur transmembranaire pour évaluer une fonction neuromusculaire
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
WO2019059868A3 (fr) Combinaisons pharmaceutiques de ténofovir, d'emtricitabine et d'éfavirenz
WO2014133746A3 (fr) Compositions pour soins d'hygiène buccale
USD731650S1 (en) Pulltop lancet